Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway
by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283
Updated on: February 03,2024
Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway
by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283
Updated on:February 03,2024
